Meeting Coverage

SABCS Video Pearls

Video Pearls from the San Antonio Breast Cancer Symposium

Promise of CTCs in Metastatic Breast Cancer Management

Patients with progressive disease could be most likely to benefit, says Julie Lang

image

Latest SABCS Video Pearls Meeting Coverage

SABCS Trials Show Improved Outcomes in Metastatic Breast Cancer

Debu Tripathy, MD walks us through some of the key findings from this year's meeting

December 27, 2022
T-DXd Shows 'Truly Remarkable' Activity in Advanced HER2-Positive Breast Cancer

Updated data solidify ADC as standard-of-care second-line therapy, says Sara Hurvitz, MD

December 20, 2022
Selective Estrogen Receptor Degraders Show Promise in Breast Cancer

François-Clément Bidard, MD, PhD, discusses results from two studies

December 13, 2022
T-DXd Consistently Better Than Second-Line Standard in HER2+ mBC

Trastuzumab deruxtecan prolonged PFS and boosted responses in all patient subgroups

January 10, 2022
HER2CLIMB: Tucatinib Boosts OS in Breast Cancer Patients With Brain Mets

Updated results show 9-month survival benefit in those with active or untreated brain metastases

December 27, 2021
Pyrotinib OS Benefit Confirmed in HER2-Positive Metastatic Breast Cancer

Amy Tiersten, MD, discusses new data from the PHOEBE trial

December 20, 2021
Invasive Lobular Breast Cancer May Have Worse Prognosis than Ductal Cancer

Analysis highlights need for further research, says Megan Kruse, MD

January 5, 2021
Anastrozole vs Tamoxifen: Similar Outcomes, Different Side Effects

Halle Moore, MD discusses the results of the IBIS-II trial

December 29, 2020
The Changing Landscape of HER2-Positive Breast Cancer

It's a niche where many new drugs are coming, says Debu Tripathy

January 13, 2020
Tucatinib Demonstrates Survival Benefit in HER2+ Breast Cancer

Study author Rashmi Murthy and Amy Tiersten discuss the HER2CLIMB trial

December 28, 2019